DK220789D0 - THE USE AND ITS USE TO REDUCE TNF SIDE EFFECTS - Google Patents

THE USE AND ITS USE TO REDUCE TNF SIDE EFFECTS

Info

Publication number
DK220789D0
DK220789D0 DK220789A DK220789A DK220789D0 DK 220789 D0 DK220789 D0 DK 220789D0 DK 220789 A DK220789 A DK 220789A DK 220789 A DK220789 A DK 220789A DK 220789 D0 DK220789 D0 DK 220789D0
Authority
DK
Denmark
Prior art keywords
side effects
reduce tnf
tnfs
tnf
reduce
Prior art date
Application number
DK220789A
Other languages
Danish (da)
Other versions
DK220789A (en
Inventor
Hubert Heuer
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of DK220789D0 publication Critical patent/DK220789D0/en
Publication of DK220789A publication Critical patent/DK220789A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paper (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)

Abstract

Concomitant administration of TNFs with a PAF antagonist allows the unwanted side effects of the TNFs to be reduced and the therapeutic index of the TNFs to be increased.
DK220789A 1988-05-11 1989-05-05 THE USE AND ITS USE TO REDUCE TNF SIDE EFFECTS DK220789A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3816169A DE3816169A1 (en) 1988-05-11 1988-05-11 USE AND AGENT FOR REDUCING THE SIDE EFFECTS OF TNF

Publications (2)

Publication Number Publication Date
DK220789D0 true DK220789D0 (en) 1989-05-05
DK220789A DK220789A (en) 1989-11-12

Family

ID=6354207

Family Applications (1)

Application Number Title Priority Date Filing Date
DK220789A DK220789A (en) 1988-05-11 1989-05-05 THE USE AND ITS USE TO REDUCE TNF SIDE EFFECTS

Country Status (13)

Country Link
EP (1) EP0341558B1 (en)
JP (1) JP2709139B2 (en)
KR (1) KR900017592A (en)
AT (1) ATE78695T1 (en)
AU (1) AU614607B2 (en)
CA (1) CA1336825C (en)
DE (2) DE3816169A1 (en)
DK (1) DK220789A (en)
ES (1) ES2042864T3 (en)
GR (1) GR3005387T3 (en)
HU (1) HUT52381A (en)
IL (1) IL90206A0 (en)
ZA (1) ZA893259B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3735525C2 (en) * 1987-10-20 1997-02-20 Korth Ruth Maria Method for determining the efficacy of paf-acether receptor antagonists
GB8926611D0 (en) * 1989-11-24 1990-01-17 Xenova Ltd Compound and its use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0287633B1 (en) * 1986-10-16 1993-07-07 The President And Fellows Of Harvard College Combinations of tumor necrosis factors and anti-inflammatory agents for treating malignant and non-malignant diseases

Also Published As

Publication number Publication date
ATE78695T1 (en) 1992-08-15
AU614607B2 (en) 1991-09-05
CA1336825C (en) 1995-08-29
JPH0276825A (en) 1990-03-16
AU3406489A (en) 1989-11-16
DK220789A (en) 1989-11-12
EP0341558A2 (en) 1989-11-15
IL90206A0 (en) 1989-12-15
ES2042864T3 (en) 1993-12-16
DE3816169A1 (en) 1989-11-23
HUT52381A (en) 1990-07-28
EP0341558A3 (en) 1990-05-09
DE58901920D1 (en) 1992-09-03
JP2709139B2 (en) 1998-02-04
ZA893259B (en) 1991-01-30
KR900017592A (en) 1990-12-19
GR3005387T3 (en) 1993-05-24
EP0341558B1 (en) 1992-07-29

Similar Documents

Publication Publication Date Title
DE69323524D1 (en) Needle-free disposable injector
DK376589D0 (en) disposable syringe
FR2617718B1 (en) PRE-FILLED SYRINGE
IT8848710A0 (en) DISPOSABLE SYRINGE
BR8907232A (en) HYPODERMIC SYRINGE
DK659388A (en) hypodermic syringe
DE68907301D1 (en) INHALATOR WITH REDUCTION OF CONSTITUTION.
DK238588D0 (en) USE OF 3- (TRIFLUORMETHYLPHENOXY) -N-METHYL-3-PHENYLPROPYLAMINE FOR THE PREPARATION OF A MEDICINE TO TREAT DIABETES
DK369385A (en) MEDICINE TO TREAT SCHIZOFRENI
DK332489A (en) RELATIONS WITH SOURCE CODILATORY EFFECT
DK440288D0 (en) MEDICINE TO TREAT DIABETES MELLITUS
DK220789A (en) THE USE AND ITS USE TO REDUCE TNF SIDE EFFECTS
DE69332576D1 (en) Glycolized cytokines
KR900701341A (en) Disposable syringe
NO894187D0 (en) THERAPEUTIC RELATIONS.
ATA254988A (en) DISPOSABLE SYRINGE
DK85290D0 (en) THERAPEUTIC EFFECTIVE RELATIONS
NO812304L (en) PHARMACEUTICAL MIXTURES WITH ANTIPHLOGISTIC, ANTIPYRETIC AND ANALGETIC EFFECT
KR890012452U (en) Desk top angle adjustment device
DK242989D0 (en) disposable syringe
ES286012Y (en) PERFECTED STOOL WITH THERAPEUTIC CHARACTER
ATA244088A (en) DISPOSABLE SYRINGE
DK162479C (en) infusion cannula
KR830003548U (en) Bed with desk and chair
ITPT920011A1 (en) SYRINGE WITH NEEDLE RETURNING AUTOMATICALLY

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment